EMARETAMIG
UNII 8P2N8N28WN

Substance Identification & Data

This profile provides standardized clinical and technical data for Emaretamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8P2N8N28WN.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3051701-97-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8P2N8N28WN

CAS Registry Number

3051701-97-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EMARETAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C187658

National Cancer Institute reference terminology for clinical and research data.

INN ID

13773

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-173

Identifier assigned by the United States Adopted Names Council.

Substance Type

Emaretamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Emaretamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Emaretamig

Common Names & Synonyms

ASP 2138 [WHO-DD]

Anti-CLDN18.2/Anti-CD3 Bispecific Antibody ASP2138

Claudin18.2 x CD3 Bispecific Antibody ASP2138

EMARETAMIG [USAN]

H-gamma1 heavy chain anti-CLDN18 (H) (1-447) [VH (Homo sapiens IGHV5-10-1*01 (89.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 1-G1v50 CH2 delE1.4 P1.3, V1.2, A1.1, 6-G1v51 CH2 K29, 14-G1v72-3 CH1 D114, CH2 E84.2, CH3 D44, E97, D100, 18-G1v82-5 CH3 D24, S26(CH1 N114>D (209), R120>K (215) (119-216), hinge 1-15 (217-231), CH2 E1.4>del, L1.3>P (234), L1.2>V (235), G1.1>A (236), S29>K (267), Q84.2>E (295) (232-340), CH3 E12 (356), M14 (358), L24>D (368), K26>S (370), N44>D (384), Q97>E (418), N100>D (421) (341-445), CHS (446-447)) (119-447)], (221-220')-disulfide with L-kappa light chain anti-CLDN18 (L') (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*02 (90.9%) Q120>S (106), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159'), V101 (197') (114'-220')]; G1(VH-CH1-h)-10mer-scFvlh-10mer-G1(h-CH2-CH3) heavy chain anti-CLDN18 and anti-CD3E (H'') (1''-720'') [G1(VH-CH1-h) (1''-221'') [VH anti-CLDN18 (Homo sapiens IGHV5-10-1*01 (89.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26''-33''.51''-58''.97''-107'')) (1''-118'') -Homo sapiens IGHG1*03v, G1m3>G1m17 CH1 K120 (CH1 R120>K (215'') (119''-216''), hinge 1-5 (217''-221''))] -10-mer bis(tetraglycyl-seryl) linker (222''-231'') -scFvlh anti-CD3E (232''-485'') [V-LAMBDA anti-CD3E Musmus/Homsap (Mus musculus IGLV1*01 (80.6%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (257''-265''.283''-285''.322''-330'')) (232''-340'') -20-mer tetrakis(glycyl-lysyl-prolyl-glycyl-seryl) linker (341''-360'') -VH anti-CD3E (Homo sapiens IGHV3-73*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (480''), CDR-IMGT [8.10.16] (386''-393''.411''-420''.459''-474'')) (361''-485'')] -10-mer bis(tetraglycyl-seryl) linker (486''-495'') -G1(h-CH2-CH3) (496''-720'') [Homo sapiens IGHG1*03v, nG1m1 CH3 E12, M14, 1-G1v50 CH2 delE1.4 P1.3, V1.2, A1.1, 6-G1v51 CH2 K29, 18-G1v82-6 CH3 Q13, K20 (hinge 7-15 (496''-504''), CH2 E1.4>del, L1.3>P (507''), L1.2>V (508''), G1.1>A (509''), S29>K (540'') (505''-613''), CH3 E12 (629''), E13>Q (630''), M14 (631''), S20>K (637'') (614''-718''), CHS (719''-720''))]]; (221''-220''')-disulfide with L-kappa light chain anti-CLDN18 (L''')(1'''-220''') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.1%) -IGKJ2*02 (90.9%) Q120>S (106'''), CDR-IMGT [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159'''), V101 (197''') (114'''-220''')]; dimer (227-500'': 230-503'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa

Immunoglobulin G1 [507-proline,508-valine,509-alanine,del-510-glycine,541-lysine,631-glutamine,638-lysine], bispecific, anti-(human claudin-18.2) (human-Mus musculus monoclonal ASP2138 VH-CH1 fragment) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal ASP2138 single-chain variable fragment VL-(GKPGS)4-VH) fusion protein with peptide linker (GGGGS)2 fusion protein with human-Mus musculus monoclonal ASP2138 γ1-chain hinge-CH2-CH3 fragment, (500→227′) (503→230′)-bis(disulfide) with immunoglobulin G1 [209′-aspartic acid,234′-proline,235′-valine,236′-alanine,del-237′-glycine,268′-lysine,296′-glutamic acid,369′-aspartic acid,371′-serine,385′-aspartic acid,419′-glutamic acid,422′-aspartic acid] anti-(human claudin-18.2) (human-Mus musculus monoclonal ASP2138 γ1-chain), disulfide with human-Mus musculus monoclonal ASP2138 κ-chain

emaretamig [INN]

immunoglobulin (H-gamma1_L-kappa)_(G1(VH-CH1-h)-10mer-scFvlh-10mer-G1(h-CH2-CH3)_L-kappa), anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], onoclonal antibody, bispecific, trivalent (emaretamig)